151 related articles for article (PubMed ID: 12202015)
1. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.
Farren CK; O'Malley S
Am J Addict; 2002; 11(3):228-34. PubMed ID: 12202015
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Farren CK; Scimeca M; Wu R; Malley SO
Drug Alcohol Depend; 2009 Jan; 99(1-3):317-21. PubMed ID: 18644685
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.
O'Malley SS; Robin RW; Levenson AL; GreyWolf I; Chance LE; Hodgkinson CA; Romano D; Robinson J; Meandzija B; Stillner V; Wu R; Goldman D
Alcohol Clin Exp Res; 2008 Jul; 32(7):1271-83. PubMed ID: 18482155
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
Pettinati HM; Oslin DW; Kampman KM; Dundon WD; Xie H; Gallis TL; Dackis CA; O'Brien CP
Am J Psychiatry; 2010 Jun; 167(6):668-75. PubMed ID: 20231324
[TBL] [Abstract][Full Text] [Related]
5. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Grinenko AIa; Krupitskiĭ EM; Zvartau EE
Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
[TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics.
Roy A
Biol Psychiatry; 1998 Oct; 44(7):633-7. PubMed ID: 9787889
[TBL] [Abstract][Full Text] [Related]
9. [Limited role of naltrexone in the treatment of opiate addiction].
van Brussel GH
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
[TBL] [Abstract][Full Text] [Related]
10. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
[TBL] [Abstract][Full Text] [Related]
11. Current pharmacotherapies of alcoholism: a U.S. perspective.
Anton RF; Swift RM
Am J Addict; 2003; 12(s1):s53-s68. PubMed ID: 14972780
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
[TBL] [Abstract][Full Text] [Related]
13. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Tsoy M; Wahlgren V; Burakov A; Masalov D; Romanova TN; Palatkin V; Tyurina A; Yaroslavtseva T; Sinha R; Kosten TR
Drug Alcohol Depend; 2013 Oct; 132(3):674-80. PubMed ID: 23683793
[TBL] [Abstract][Full Text] [Related]
16. [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].
Krupitskiĭ EM; Zvartau EE; Tsoĭ-Podosenin MV; Masalov DV; Burakov AM; Egorova VIu; Didenko TIu; Romanova TN; Ivanova EB; Bespalov AIu; Verbitskaia EV; Neznanov NG; Grineneko AIa; O'Brien C; Woody D
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 2):44-54. PubMed ID: 21322147
[TBL] [Abstract][Full Text] [Related]
17. Oral naltrexone maintenance treatment for opioid dependence.
Minozzi S; Amato L; Vecchi S; Davoli M; Kirchmayer U; Verster A
Cochrane Database Syst Rev; 2006 Jan; (1):CD001333. PubMed ID: 16437431
[TBL] [Abstract][Full Text] [Related]
18. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Hermes G; Hyman SM; Fogelman N; Kosten TR; Sinha R
Am J Addict; 2019 Nov; 28(6):480-488. PubMed ID: 31448846
[TBL] [Abstract][Full Text] [Related]
19. A naltrexone double blind placebo controlled study in Israel.
Lerner A; Sigal M; Bacalu A; Shiff R; Burganski I; Gelkopf M
Isr J Psychiatry Relat Sci; 1992; 29(1):36-43. PubMed ID: 1568861
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts.
Landabaso MA; Iraurgi I; Jiménez-Lerma JM; Sanz J; Fernádez de Corres B; Araluce K; Calle R; Gutiérrez-Fraile M
Addiction; 1998 May; 93(5):739-44. PubMed ID: 9692272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
